EP 1032385 A1 20000906 - USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELLPROLIFERATION, DIARRHE AND SCOURS
Title (en)
USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELLPROLIFERATION, DIARRHE AND SCOURS
Title (de)
VERWENDUNG VON SUBSTITUIERTEN DIPHENYL INDANONE, INDAN UND INDOL DERIVATE ZUR BEHANDLUNG ODER VORBEUGUNG VON SICHELZELLANÄMIE, ENTZÜNTLICHEN ERKRANKUNGEN, DIE DURCH ABNORMALE ZELLPROLIFERATION GEKENZEICHNET SIND, DIARRHÖE UND DIARRHÖE BEI TIEREN
Title (fr)
UTILISATION DE COMPOSES DE DIPHENYLE INDANONE, INDANE ET INDOLE SUBSTITUES DANS LE TRAITEMENT OU LA PREVENTION DE LA DREPANOCYTOSE, DES MALADIES INFLAMMATOIRES CARACTERISEES PAR UNE PROLIFERATION CELLULAIRE ANORMALE ET PAR LA DIARRHEE CHEZ L'HOMME ET L'ANIMAL
Publication
Application
Priority
- US 9824968 W 19981120
- US 97559597 A 19971120
- US 15933698 A 19980923
- US 15933198 A 19980923
Abstract (en)
[origin: WO9926624A1] The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof which are specific, potent and safe inhibitors of the Ca<2+>-activated potassium channel (Gardos channel) of erythrocytes, of mammalian cell proliferation and/or of secretagogue-stimulated transepithelial electrogenic chloride secretion in intestinal cells. The compounds can be used to reduce sickle erytrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation in situ as a therapeutic approach towards the treatment or prevention of sickle cell disease. The compounds can also be used to inhibit mamalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation. Furthermore, the compounds can also be used to inhibit chloride secretion in intestinal cells as a therapeutic approach towards the treatment of diarrhea and scours.
IPC 1-7
IPC 8 full level
C07D 317/20 (2006.01); A61K 31/045 (2006.01); A61K 31/075 (2006.01); A61K 31/12 (2006.01); A61K 31/122 (2006.01); A61K 31/15 (2006.01); A61K 31/165 (2006.01); A61K 31/216 (2006.01); A61K 31/222 (2006.01); A61K 31/235 (2006.01); A61K 31/277 (2006.01); A61K 31/336 (2006.01); A61K 31/357 (2006.01); A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 35/20 (2006.01); A61P 1/00 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 29/00 (2006.01); A61P 37/02 (2006.01); A61P 43/00 (2006.01); C07D 209/14 (2006.01)
CPC (source: EP)
A61K 31/045 (2013.01); A61K 31/075 (2013.01); A61K 31/122 (2013.01); A61K 31/15 (2013.01); A61K 31/165 (2013.01); A61K 31/216 (2013.01); A61K 31/222 (2013.01); A61K 31/235 (2013.01); A61K 31/277 (2013.01); A61K 31/336 (2013.01); A61K 31/357 (2013.01); A61K 31/404 (2013.01); A61K 35/20 (2013.01); A61P 1/00 (2017.12); A61P 9/00 (2017.12); A61P 9/10 (2017.12); A61P 13/12 (2017.12); A61P 17/00 (2017.12); A61P 29/00 (2017.12); A61P 37/02 (2017.12); A61P 43/00 (2017.12)
Citation (search report)
See references of WO 9926624A1
Designated contracting state (EPC)
AT BE CH DE ES FR GB IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9926624 A1 19990603; AU 1598899 A 19990615; CA 2311129 A1 19990603; EP 1032385 A1 20000906; IL 136208 A0 20010520; JP 2001523717 A 20011127
DOCDB simple family (application)
US 9824968 W 19981120; AU 1598899 A 19981120; CA 2311129 A 19981120; EP 98960381 A 19981120; IL 13620898 A 19981120; JP 2000521826 A 19981120